-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Climb Bio, Raises Price Target to $32

Benzinga·09/03/2026 18:14:06
Listen to the news
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.